{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:48:22Z","timestamp":1791920902934,"version":"4.3.4"},"reference-count":19,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,6,18]]},"DOI":"10.1182\/blood.2019004602","type":"journal-article","created":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T21:31:56Z","timestamp":1586554316000},"page":"2316-2319","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":55,"title":["Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus\u2013associated multicentric Castleman disease"],"prefix":"10.1182","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5709-4675","authenticated-orcid":false,"given":"Ramya","family":"Ramaswami","sequence":"first","affiliation":[{"name":"HIV & AIDS Malignancy Branch,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5794-7292","authenticated-orcid":false,"given":"Kathryn","family":"Lurain","sequence":"first","affiliation":[{"name":"HIV & AIDS Malignancy Branch,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9395-3473","authenticated-orcid":false,"given":"Cody J.","family":"Peer","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Program, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5629-6099","authenticated-orcid":false,"given":"Anna","family":"Serqui\u00f1a","sequence":"first","affiliation":[{"name":"HIV & AIDS Malignancy Branch,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Wang","sequence":"first","affiliation":[{"name":"HIV & AIDS Malignancy Branch,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anaida","family":"Widell","sequence":"first","affiliation":[{"name":"HIV & AIDS Malignancy Branch,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscila","family":"Goncalves","sequence":"first","affiliation":[{"name":"HIV & AIDS Malignancy Branch,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M.","family":"Steinberg","sequence":"first","affiliation":[{"name":"Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickie","family":"Marshall","sequence":"first","affiliation":[{"name":"Viral Oncology Section, AIDS and Cancer Virus Program, Leidos-Biomedical, Frederick National Laboratory for Cancer Research, Frederick, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jomy","family":"George","sequence":"first","affiliation":[{"name":"Clinical Pharmacokinetics Research Laboratory, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Figg","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Program, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Whitby","sequence":"first","affiliation":[{"name":"Viral Oncology Section, AIDS and Cancer Virus Program, Leidos-Biomedical, Frederick National Laboratory for Cancer Research, Frederick, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Ziegelbauer","sequence":"first","affiliation":[{"name":"HIV & AIDS Malignancy Branch,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Uldrick","sequence":"first","affiliation":[{"name":"HIV & AIDS Malignancy Branch,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3057-1395","authenticated-orcid":false,"given":"Robert","family":"Yarchoan","sequence":"first","affiliation":[{"name":"HIV & AIDS Malignancy Branch,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2020061811292268400_B1","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJMra1615896","article-title":"HIV-associated cancers and related diseases","volume":"378","author":"Yarchoan","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2020061811292268400_B2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.hoc.2017.09.007","article-title":"Treatment of Kaposi sarcoma herpesvirus-associated multicentric Castleman disease","volume":"32","author":"Lurain","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"issue":"22","key":"2020061811292268400_B3","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2010-07-290213","article-title":"How I treat HIV-associated multicentric Castleman disease","volume":"116","author":"Bower","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2020061811292268400_B4","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1182\/blood.V97.8.2526","article-title":"Serum viral interleukin-6 in AIDS-related multicentric Castleman disease","volume":"97","author":"Aoki","year":"2001","journal-title":"Blood"},{"issue":"26","key":"2020061811292268400_B5","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1182\/blood-2013-08-519959","article-title":"Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease","volume":"122","author":"Polizzotto","year":"2013","journal-title":"Blood"},{"issue":"22","key":"2020061811292268400_B6","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2011-09-377705","article-title":"HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice","volume":"119","author":"Suthaus","year":"2012","journal-title":"Blood"},{"issue":"26","key":"2020061811292268400_B7","doi-asserted-by":"crossref","first-page":"6977","DOI":"10.1182\/blood-2010-11-317610","article-title":"High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy","volume":"117","author":"Uldrick","year":"2011","journal-title":"Blood"},{"issue":"22","key":"2020061811292268400_B8","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1200\/JCO.2007.10.6732","article-title":"Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman\u2019s disease: ANRS 117 CastlemaB trial","volume":"25","author":"G\u00e9rard","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020061811292268400_B9","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/0003-4819-147-12-200712180-00003","article-title":"Brief communication: rituximab in HIV-associated multicentric Castleman disease","volume":"147","author":"Bower","year":"2007","journal-title":"Ann Intern Med"},{"issue":"24","key":"2020061811292268400_B10","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1182\/blood-2014-07-586800","article-title":"Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease","volume":"124","author":"Uldrick","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2020061811292268400_B11","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1182\/blood-2003-03-0951","article-title":"Rituximab therapy for HIV-associated Castleman disease","volume":"102","author":"Marcelin","year":"2003","journal-title":"Blood"},{"issue":"15","key":"2020061811292268400_B12","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2016-10-747477","article-title":"Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients","volume":"129","author":"Pria","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2020061811292268400_B13","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1182\/blood-2007-08-106187","article-title":"Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease","volume":"110","author":"Powles","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2020061811292268400_B14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00296-008-0703-8","article-title":"Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling","volume":"29","author":"Hashizume","year":"2009","journal-title":"Rheumatol Int"},{"issue":"8","key":"2020061811292268400_B15","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease","volume":"106","author":"Nishimoto","year":"2005","journal-title":"Blood"},{"issue":"10","key":"2020061811292268400_B16","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1182\/blood.V98.10.3042","article-title":"Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirus","volume":"98","author":"Aoki","year":"2001","journal-title":"Blood"},{"issue":"10","key":"2020061811292268400_B17","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0198-8859(99)00083-X","article-title":"KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways","volume":"60","author":"Osborne","year":"1999","journal-title":"Hum Immunol"},{"issue":"9","key":"2020061811292268400_B18","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.1989.7.9.1201","article-title":"Kaposi\u2019s sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria","volume":"7","author":"Krown","year":"1989","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020061811292268400_B19","doi-asserted-by":"crossref","first-page":"ofy217","DOI":"10.1093\/ofid\/ofy217","article-title":"Emergence of Kaposi\u2019s sarcoma herpesvirus-associated complications following corticosteroid use in TB-IRIS","volume":"5","author":"Manion","year":"2018","journal-title":"Open Forum Infect Dis"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/25\/2316\/1744735\/bloodbld2019004602.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/25\/2316\/1744735\/bloodbld2019004602.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T15:55:22Z","timestamp":1592495722000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/25\/2316\/454362\/Tocilizumab-in-patients-with-symptomatic-Kaposi"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,18]]},"references-count":19,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2020,6,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019004602","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,18]]}}}